TY - JOUR
T1 - 'Above all do no harm:' Horizons in pediatric oncology
AU - Weitman, S. D.
AU - Winick, N. J.
AU - Kamen, B. A.
PY - 1994/1/1
Y1 - 1994/1/1
N2 - The articles selected in this review highlight some advances in the use of the 'old standards' methotrexate and 6-mercaptopurine for the treatment of children with acute lymphoblastic leukemia, especially the laboratory studies, which may allow a 'pharmacologic phenotyping' to identify children most likely to relapse. In addition, we review the use of 'newer' drugs (epipodophyllotoxins), which may be effective but are also associated with high morbidity (ie, secondary acute myeloid leukemia). As a second issue, 'dose intensity' and the use of high-dose chemotherapy followed by bone marrow transplantation will be challenged, especially in light of peripheral stem cell harvest and the use of growth factors.
AB - The articles selected in this review highlight some advances in the use of the 'old standards' methotrexate and 6-mercaptopurine for the treatment of children with acute lymphoblastic leukemia, especially the laboratory studies, which may allow a 'pharmacologic phenotyping' to identify children most likely to relapse. In addition, we review the use of 'newer' drugs (epipodophyllotoxins), which may be effective but are also associated with high morbidity (ie, secondary acute myeloid leukemia). As a second issue, 'dose intensity' and the use of high-dose chemotherapy followed by bone marrow transplantation will be challenged, especially in light of peripheral stem cell harvest and the use of growth factors.
UR - http://www.scopus.com/inward/record.url?scp=0028206163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028206163&partnerID=8YFLogxK
U2 - 10.1097/00008480-199404000-00017
DO - 10.1097/00008480-199404000-00017
M3 - Review article
C2 - 8032404
AN - SCOPUS:0028206163
SN - 1040-8703
VL - 6
SP - 219
EP - 223
JO - Current opinion in pediatrics
JF - Current opinion in pediatrics
IS - 2
ER -